相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis
T. Graier et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study
J. F. B. Schwensen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab
Heena Mehta et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Z. Z. N. Yiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Drug survival in patients with psoriasis is associated with the availability of biologic medications
G. Shalom et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Guselkumab in the treatment of moderate-to-severe plaque psoriasis
Cristina Lopez-Sanchez et al.
IMMUNOTHERAPY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Psoriasis Pathogenesis and Treatment
Adriana Rendon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
Alexander Egeberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study
Tiago Torres et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis
A. Mourad et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis
Tomaz Lunder et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry
L. S. van Der Schoot et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival
Antonio Costanzo et al.
DERMATOLOGY (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR
Kayleigh J. Mason et al.
JAMA DERMATOLOGY (2018)
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Pei-Tzu Lin et al.
SCIENTIFIC REPORTS (2018)
A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis
Yifan Hu et al.
CLINICAL DRUG INVESTIGATION (2018)
Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary
Lilla Pogacsas et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis
Boguslaw Nedoszytko et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2017)
Comment on Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis
J. M. P. A. van den Reek et al.
ACTAS DERMO-SIFILIOGRAFICAS (2017)
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls
Juul M. P. A. van den Reek et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
J. M. Carrascosa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland
P. M. Laws et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
分享论文
